Compounds and methods for treating cancer
AssigneeIGF Oncology, LLC
InventorHugh McTavish
Life of this patent
Estimating the term…
Abstract
The present invention provides a method of treating cancer involving administering an insulin-like growth factor-1 receptor (IGF-1 receptor) agonist and an anti-cancer chemotherapeutic agent. Also provided are compounds for treating cancer comprising an IGF-1-receptor ligand coupled to an anti-cancer chemotherapeutic agent. Also provided are compounds for treating cancer comprising an insulin-receptor ligand coupled to an anti-cancer chemotherapeutic agent.
Claims11
A compound for treating cancer comprising:
- an anti-cancer chemotherapeutic agent linked to
- an insulin-like growth factor-1 (IGF-1) receptor ligand;
- wherein the IGF-1 receptor ligand is a variant IGF-1 that has reduced binding affinity for soluble IGF-1 binding proteins compared to wild-type IGF-1
- wherein the variant IGF-1 comprises the polypeptide structure A1-A2-A3-A4-LCG-A5-A6-LV-A7-AL-A8-A9-R1, wherein
- A1 is G, V, or FV;
- A2 is P or N;
- A3 is E or Q;
- A4 is T, H, or A;
- A5 is A or S;
- A6 is E or H;
- A7 is D or E;
- A8 is Q or Y;
- A9 is F or L;
- and
- R1 is SEQ ID NO:6;
- provided the variant IGF-1 does not consist of SEQ ID NO:1;
- wherein the variant IGF-1 does not comprise SEQ ID NO:11.
2-5. (canceled)
The compound of claim 4 wherein the anti-cancer chemotherapeutic agent is linked to IGF-1 through an amino group of IGF-1.
12-13. (canceled)
15-21. (canceled)
Dependencies are inferred from the claim text.